EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%
Yazar
Gogishvili, M.
Sezer, A.
Kilickap, S.
Gumus, M.
Bondarenko, I.
ÖZGÜROĞLU, Mustafa
TÜRK, HACI MEHMET
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Li, S.
Lee, S.
Gullo, G.
Lowy, I.
Rietschel, P.
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]